MICHAEL R MIGDEN to Survival Rate
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Survival Rate.
Connection Strength
0.103
-
PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. Australas J Dermatol. 2022 Feb; 63(1):36-42.
Score: 0.076
-
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381.
Score: 0.014
-
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5.
Score: 0.013